This report is a systematic analysis of a multitude of different research papers and conducted trials with regards to CBD’s impact on a multitude of different mental health conditions, covering social anxiety disorder (SAD), and autism spectrum disorder (ASD), as well as attention deficit hyperactivity disorder (ADHD).
This study collated case reports, case series, open-label trials, non-randomized and randomized controlled trials (RCTs) for cross-analysis. The search resulted in 23 relevant studies on CBD and nabiximols (Sativex) in the treatment of a wide range of psychiatric disorders. The studies were judged on a “Levels of Evidence” scale, ranging from level 1 to level 5 based on the quality and study design of the reports being analysed. These levels of evidence then led to a grading of recommendations of CBD being used in treatment for different conditions, ranging from Grade A (strong recommendation) to Grade D (weakest recommendation).
The results stated that there is Grade B recommendation supporting the use of CBD for the treatment of schizophrenia, social anxiety disorder and autism spectrum disorder (ASD), and attention deficit hyperactivity disorder (ADHD).
Goodbody has no association with the organisation that conducted this research and is not in a position to validate the research methods, results or conclusions of the published article. It is provided for awareness of research available that may be of interest only. Any reader should read a range of articles and research to have a balanced and informed view.